Medicare prescription drug cost, prescriptions and prescribers, 2024
Medicare cost, 2024
$199.8M
+103.4% from 2023
Prescriptions
659K
$303.00 per claim
Patients
182K
95,723 prescribers
Total spending, 2024
$199.9M
$1,099.19 per patient
Medicare prescription drug plans paid $199.8M for Arnuity Ellipta in 2024, for 659,289 prescriptions and refills to 181,748 patients (up 103.4% from 2023). The average cost per claim was $303.00.
New York had the highest Medicare cost for Arnuity Ellipta in 2024: $16.8M for 57,202 claims, followed by California ($14.8M).
Reuven Moshenyat, pulmonary disease in Brooklyn, NY, had the highest Medicare cost for Arnuity Ellipta in 2024: 2,723 claims costing $731K.
Arnuity Ellipta is made by GSK plc (GSK), listed in the Medicare spending data as Glaxosmithkline.
All plans and makers
Where the prescribers practice, 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| Reuven Moshenyat Brooklyn, NY | Pulmonary Disease | 2,723 | 666 | $731K |
| Reinaldo Gonzalez Martinez Bayamon, PR | Pulmonary Disease | 1,623 | 345 | $360K |
| Luis C Torrellas Ruiz |
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 40,987 | 285,826 | 67,918 | $88.8M |
| 2023 | 45,547 | 289,413 | 74,780 | $98.2M |
| 2024 | 95,723 | 659,289 | 181,748 | $199.8M |
Amount reimbursed by state Medicaid programs, all states
More drugs: top Medicare drugs by cost and the Prescriptions tab.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
| Pulmonary Disease |
| 1,527 |
| 325 |
| $345K |
| Luis F Velez-Quinones Arecibo, PR | Internal Medicine | 1,188 | 260 | $255K |
| Thomas K Chan New York, NY | Pulmonary Disease | 824 | 112 | $185K |
| Essam R Awad Fall River, MA | Pulmonary Disease | 559 | 128 | $170K |
| Zulmari Campos Santiago Cayey, PR | Pulmonary Disease | 607 | 98 | $161K |
| Alan S Chanales Rockville, MD | Pulmonary Disease | 482 | 130 | $159K |
| Samuel Suarez Baez San Juan, PR | Pulmonary Disease | 714 | 164 | $156K |
| Oscar Rivera Caguas, PR | Pulmonary Disease | 611 | 170 | $130K |
| Carlos A Obregon Sewell, NJ | Pulmonary Disease | 316 | 91 | $122K |
| Emanuel I Wurm Somers, NY | Pulmonary Disease | 407 | 119 | $121K |
| Adel Sandouk Glendora, CA | Pulmonary Disease | 501 | 115 | $115K |
| Christopher Faber Pittsburgh, PA | Pulmonary Disease | 372 | 92 | $115K |
| Michel R Samaha Milford, DE | Pulmonary Disease | 323 | 73 | $107K |
| Mohammad D Khamiees Cumberland, RI | Pulmonary Disease | 288 | 109 | $106K |
| Farid A Irshad Cumberland, RI | Physician Assistant | 320 | 129 | $102K |
| Raymond D Petit Attleboro, MA | Critical Care (Intensivists) | 312 | 70 | $99K |
| Juan J Candelario Lanza Caguas, PR | Pulmonary Disease | 335 | 87 | $95K |
| Pamela F Wright Sevierville, TN | Nurse Practitioner | 227 | 83 | $90K |
| John J Costa Buzzards Bay, MA | Allergy/ Immunology | 233 | 62 | $87K |
| Jason B Karp Lake Success, NY | Pulmonary Disease | 170 | 48 | $87K |
| Nestor J Flores Guayama, PR | Pulmonary Disease | 390 | 82 | $84K |
| Steven Johnson Racine, WI | Pulmonary Disease | 246 | 64 | $83K |
| Heather N Hartman Cincinnati, OH | Allergy/ Immunology | 196 | 39 | $82K |
Spending by manufacturer as listed in the spending data
| Manufacturer | Claims | Spending |
|---|---|---|
| Glaxosmithkline GSK | 659,581 | $199.9M |